Additionally, hepatic SLC13A5 expression correlated positively with both body and liver fat in a cohort of non-alcoholic fatty liver disease (NAFLD) patients (von Loeffelholz et al., 2017). Here, SLC13A5 is linked to metabolic dysfunction-associated steatotic liver disease.